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There are two populations of T-cells that are characterized by the type of T-cell receptor (TCR) that 
is expressed: αß and γδ.  The majority of T-cells express αß TCRs while only 2% of total T-cells 
have TCRs made of γδ subunits.  Furthermore, a specific type of γδ T-cell that expresses 
γ9δ2TCRs, a class of innate immune cells, can be highly anti-tumorgenic in mouse cancer 
models.  However, adoptive transfer of γ9δ2 cells in the clinic has provided less tumor control.  The 
Strong (Basic Sciences Division) and Kuball (UMC Utrecht, The Netherlands) labs investigated two 
important questions: what is the molecular defect curtailing the anti-tumor effectiveness of γ9δ2T-cell 
therapy and can this weakness be ameliorated to increase their therapeutic potential? 
As a starting point, γ9δ2T-cells from a healthy donor were cloned and their reactivity against a panel 
of tumor cells was assessed by an IFNγ ELISA assay.  Individual clones of γ9δ2T-cells displayed 
differential recognition of and activation by specific tumor cells.  They hypothesized that the strength 
of the anti-tumor response correlated with differences in γ9δ2TCR amino-acid sequence.  To test 
this, the γδ chains of a T-cell clone with strong functional avidity was sequenced and compared to a 
T-cell clone that displayed a weak response in the ELISA assay.  Interestingly, only the CDR3 
domain of the receptors contained amino acid changes.  To determine if the amino acid changes 
influenced TCR function, the mutant receptors that displayed increased functionality and wild-type 
control receptors were transduced into peripheral blood αßT-cells and T-cell activity against tumor 
cells was determined.  Indeed, αßT-cells expressing the stronger γ9δ2TCR had a greater ability to 
lyse tumor cells and secrete IFNγ compared to wild-type γ9δ2TCR-expressing αßT-cells.  Thus, the 
CDR3 domain of the γ9δ2TCR is a critical determinant of TCR functionality. 
Mutational analysis of CDR3 domain residues in both the γ9 and δ2 chains of wild-type receptors 
revealed that too short (no amino acid addition) and very long (12 amino acid) alanine stretches in a 
particular CDR3 region negatively affect receptor function.  To determine if an optimal CDR3 length 
exists, they searched the ImMunoGeneTics database for stretches of amino acids in the CDR3 
regions of the γ9δ2TCRs.  The majority of listed γ9δ2TCRs contained a conservative number of 
residues (5-7 amino acids) in the CDR3 domain, indicating that those TCRs have a functional 
advantage and are under positive selection.  In addition, single point mutations in both chains of the  
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γ9δ2TCRs were found to influence TCR functional avidity.  Lastly, CTE (combinatorial-γδTCR-chain-
exchange) was used to engineer γ9δ2TCRs that were predicted to have increased receptor function 
based on the aforementioned results.  Astoundingly, αßT-cells expressing the CTE-engineered 
γ9δ2TCRs were highly reactive against a broad range of tumors and did not affect normal tissue in 
the IFNγ ELISA.  When tested in a humanized mouse model, the CTE-engineered γ9δTCRs 
decreased tumor outgrowth and increased the overall survival of the mice.  Taken together, these 
data indicate that CTE-engineered TCRs are a promising candidate for clinical application and may 
prove useful for future anti-cancer therapy.  
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A scanning electron micrograph of a T 
lymphocyte (Tc) recognizing and 
attaching to an antigen presenting cell 
(APC). 
 
